Artificial Intelligence-Assisted Amphiregulin and Epiregulin IHC Predicts Panitumumab Benefit in RAS Wild-Type Metastatic Colorectal Cancer.

Christopher J M Williams Jenny F SeligmannFaye ElliottMichael ShiresSusan D RichmanSarah BrownLiping ZhangShalini SinghJudith PughXiao-Meng XuAndrea Muranyi Christoph GuetterAuranuch LorsakulUday KurkureZuo ZhaoJim MartinXingwei WangKien NguyenWen-Wei LiuDongyao YanNicholas P West Jennifer H BarrettMichael BarnesIsaac BaiMatthew T Seymour Philip QuirkeKandavel Shanmugam

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

AREG/EREG IHC identified patients who benefitted from the addition of panitumumab to irinotecan chemotherapy. IHC is a practicable assay that may be of use in routine practice.

Keyphrases

wild type
artificial intelligence
metastatic colorectal cancer
machine learning
big data
deep learning
healthcare
primary care
high throughput
locally advanced
radiation therapy